NCT00908596View on ClinicalTrials.gov

Primovist / Eovist in Renally Impaired Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

357

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Contrast Media
Interventions
DRUG

Gadoxetic acid disodium (Primovist, BAY86-4873)

Primovist/Eovist in approved indications at approved dosages

Trial Locations (47)

1090

Vienna

2145

Westmead NSW

3220

Geelong

4029

Herston

4102

Woollongabba

5000

Adelaide

8036

Graz

10021

New York

10060

Candiolo

10700

Bangkok

11219

Brooklyn

12200

Berlin

18012

Granada

20089

Rozzano

20141

Milan

21287

Baltimore

25123

Brescia

27710

Durham

30625

Hanover

32209

Jacksonville

35033

Marburg

38104

Memphis

39120

Magdeburg

44137

Dortmund

45122

Essen

48109

Ann Arbor

56124

Pisa

60596

Frankfurt am Main

66604

Topeka

69120

Heidelberg

70376

Stuttgart

77030

Houston

78229

San Antonio

80078

Pozzuoli

80131

Napoli

90033

Los Angeles

90110

Songkhla

90127

Palermo

91054

Erlangen

96813

Honolulu

01307

Dresden

07548

Gera

602-739

Busan

Unknown

Seoul

Bangkok

138-736

Seoul

BS10 5NB

Bristol

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00908596 - Primovist / Eovist in Renally Impaired Patients | Biotech Hunter | Biotech Hunter